» Articles » PMID: 16550575

Extended Lymph Node Dissection Without Routine Spleno-pancreatectomy for Treatment of Gastric Cancer: Low Morbidity and Mortality Rates in a Single Center Series of 250 Patients

Overview
Journal J Surg Oncol
Date 2006 Mar 22
PMID 16550575
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: To verify the hypothesis that avoidance of routine splenectomy and distal pancreatectomy in a modified D-2 resection for gastric cancer can significantly lower the complications rate of this procedure in a population of Western patients.

Methods: A series of 250 consecutive Italian patients suffering from localized, histology-proven gastric cancer was submitted to gastrectomy and extended D-2 lymphadenectomy for treatment of their disease during an 8-year period (1994-2002) at the European Institute of Oncology in Milano, Italy. Caudal pancreas and spleen were routinely preserved, unless the tumor was not closely adjacent to or directly invading these organs. Postoperative morbidity, overall mortality, and length of hospital stay were recorded.

Results: One hundred forty patients underwent total gastrectomy and 110 a subtotal distal one; splenectomy was performed in 8 cases and spleno-pancreatectomy in 15. The postoperative morbidity rate was 18%, the mortality rate was 1.2% and 9 patients experienced re-operation. The median length of stay was 14.8 days.

Conclusions: These results compete favorably with those reported after standard D-1 gastrectomy in Western patients series. D-2 gastrectomy with spleen and pancreas routine preservation can be considered a safe treatment for gastric cancer in Western patients, at least in experienced centers.

Citing Articles

Systemic Review and Meta-analysis of Impact of Splenectomy for Advanced Gastric Cancer.

Kunisaki C, Sato S, Tsuchiya N, Watanabe J, Sato T, Takeda K In Vivo. 2020; 34(6):3115-3125.

PMID: 33144415 PMC: 7811676. DOI: 10.21873/invivo.12145.


Gastrectomy with D2 Lymphadenectomy for Carcinoma of the Stomach in a Stand-alone Cancer Centre in Rural India.

Pareekutty N, Kadam S, Ankalkoti B, Balasubramanian S, Anilkumar B Indian J Surg Oncol. 2020; 11(2):256-262.

PMID: 32523272 PMC: 7260343. DOI: 10.1007/s13193-020-01059-w.


Comparative Effectiveness of Lymphadenectomy Strategies During Curative Resection for Gastric Adenocarcinoma.

Hu Y, McMurry T, Goudreau B, Leick K, Le T, Zaydfudim V J Gastrointest Surg. 2019; 24(10):2212-2218.

PMID: 31515762 PMC: 7065947. DOI: 10.1007/s11605-019-04393-9.


Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: A systematic review and meta-analysis.

Luo H, Wu L, Huang M, Jin Q, Qin Y, Chen J Medicine (Baltimore). 2018; 97(43):e12932.

PMID: 30412102 PMC: 6221738. DOI: 10.1097/MD.0000000000012932.


Survival outcomes after D1 and D2 lymphadenectomy with R0 resection in stage II-III gastric cancer: Longitudinal follow-up in a single center.

Uslu A, Zengel B, Ilhan E, Aykas A, Simsek C, Ureyen O Turk J Surg. 2018; 34(2):125-130.

PMID: 30023977 PMC: 6048646. DOI: 10.5152/turkjsurg.2018.3846.